EMA recommends Nuvaxovid for authorisation in the EU

EMA

20 December 2021 - EMA has recommended granting a conditional marketing authorisation for Novavax’s COVID-19 vaccine Nuvaxovid (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age.

Nuvaxovid is the fifth vaccine recommended in the EU for preventing COVID-19.

Read EMA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Europe , Vaccine , COVID-19